Telehealth News & Price Updates (2026)
Regulatory actions, pricing changes and company news across D2C telehealth, with what each one costs the patients who use these brands.
FTC and states sue Hims & Hers over billing and cancellation
The FTC, Utah and Los Angeles County allege Hims & Hers billed customers without consent and blocked easy cancellation. The company denies it.
Fridays renames its sale each season as the price stays the same
Seven Internet Archive captures of the Fridays pricing page show identical compounded GLP-1 prices under four seasonal sale banners, and a no-sale variant.
Amazon One Medical extends GLP-1 care to 48 states at $39 a visit
Amazon's One Medical GLP-1 program now covers 48 states and Washington, D.C. Cash-pay visits cost $39 or $59, and Amazon says no membership is required.
LifeMD cuts Zepbound vial price, raises advertised copay figure
LifeMD's advertised Zepbound vial price fell from $349 to $299 between August 11 and September 10, while its headline copay claim rose from $0 to $25.
Mochi cuts compounded semaglutide to $60 and tirzepatide to $90
Archived captures of joinmochi.com show compounded semaglutide fell from $99 to $60 and tirzepatide from $199 to $90 sometime after mid-July.
Medicare's GLP-1 Bridge puts branded GLP-1s at $50 a month
A federal initiative opening July 1 prices Wegovy, Foundayo and the Zepbound KwikPen at $50 a month for some Part D members. WeightWatchers plugged in.
Noom buys a 503A pharmacy the week FDA restates compounding limits
Noom closed its purchase of Tailor Made Compounding, a 503A pharmacy licensed in 46 states, the same day the FDA restated its GLP-1 compounding conditions.
FDA approves Lilly's Foundayo pill at $149 a month self-pay
The FDA approved Eli Lilly's orforglipron on April 1. Lilly set self-pay from $149 a month, below what most GLP-1 programs in our price database charge.
FDA sets out compounding limits for semaglutide and tirzepatide
The FDA restated the conditions compounders must meet for semaglutide and tirzepatide: four prescriptions a month, and no shortage-list cover.
Novo Nordisk launches prepaid Wegovy subscriptions from $249/mo
Novo Nordisk opened prepaid three-, six- and 12-month Wegovy subscriptions on March 31 through Ro, WeightWatchers and LifeMD, from $249/mo.
Hims & Hers drops compounded GLP-1s as Novo Nordisk drops suit
Hims & Hers will stop advertising compounded GLP-1s and sell branded Ozempic and Wegovy instead. Novo Nordisk dismissed its lawsuit the same day.